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STRUCTURED SUMMARY 21 
Aim: To systematically examine and quantify the efficacy and safety of Tranexamic acid in 22 
hip fracture surgery. 23 
Methods: A systematic literature search was conducted using Medline, EMBASE, AMED, 24 
CiNAHL, and the Cochrane Central Registry of Controlled Trials. Two assessors 25 
independently screened search outputs for potentially relevant articles which met the 26 
eligibility criteria. The primary outcome measure was requirement of post-operative blood 27 
transfusion. Risk of bias assessment was performed using the Cochrane Collaboration’s risk 28 
of bias tool for RCT’s and the ROBINS-I tool for observational studies. Meta-analysis was 29 
performed to estimate risk ratio (RR), risk difference (RD) and mean difference (MD) values 30 
for dichotomous and continuous data outcomes respectively. The interpretation of each 31 
outcome was made using the GRADE approach. 32 
Results: Of 102 studies identified, seven met the inclusion criteria including a total of 770 33 
participants (TXA: 341; Control: 429). On meta-analysis, intra-venous TXA resulted in a 46% 34 
risk reduction in blood transfusion requirement compared to a placebo/control group 35 
(RR:0.54; 95% CI: 0.35 to 0.85; I2: 78%; Inconsistency (Chi2) p=<0.0001; N=750). There was 36 
also a significantly higher post-operative haemoglobin for TXA versus placebo/control 37 
(MD:0.81; 95% CI: 0.45 to 1.18; I2: 46%; Inconsistency (Chi2)  p=0.10; N=638). There was 38 
no increased risk of thromboembolic events (RD:0.01; 95% CI: -0.03, 0.05; I2: 68%; 39 
Inconsistency (Chi2) p=0.007, N=683). 40 
Conclusion: There is moderate quality evidence that TXA reduces blood transfusion in hip 41 
fracture surgery, with low quality evidence suggesting no increased risk of thrombotic 42 
events. These findings are consistent with TXA use in other orthopaedic procedures. 43 
 44 
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INTRODUCTION 50 
Despite modern healthcare advances, hip fractures still remain a major risk group for in-51 
hospital mortality, with figures as high as 15% [1, 2]. These deaths typically happen early in 52 
the post-operative period, with a mean of 11 days from admission [3].  53 
Peri-operative blood loss is a common complication of hip fracture surgery that has been 54 
linked to post-operative mortality [4]. Blood loss in people who undergo hip fracture surgery 55 
is often significant [5], and is likely underestimated by standard intra-operative calculations 56 
[6]. In addition post-operative anaemia has been linked to increased impairment of functional 57 
ability, longer length of hospital stay and increased mortality [4, 7, 8]. 58 
Typical management of post-operative anaemia is through blood transfusion, Major 59 
orthopaedic surgery has been identified as the commonest indication for blood transfusion in 60 
surgical patients [9]. There is however concern regarding a significantly increased risk of 61 
serious bacterial infection in hip fracture patients undergoing allogenic blood transfusion [10]. 62 
The most recent Serious Hazards of Transfusion report (SHOT) found evidence for 15 63 
transfusion-related deaths and 169 incidences of major morbidity associated with blood 64 
transfusion in 2014 within the UK alone [11]. 65 
One potential method of decreasing peri-operative blood loss and reducing post-operative 66 
transfusion is through the use of Tranexamic acid (TXA). This is an anti-fibrinolytic agent 67 
which blocks the lysine binding site of plasminogen [12]. Current evidence suggests that 68 
TXA reduces peri-operative blood loss and transfusion rates across a range of surgical 69 
disciplines without an increased risk of thrombosis [12-15]. 70 
Scientific rationale and supporting evidence suggests that TXA may be useful in reducing 71 
blood loss and transfusion rates in hip fracture surgery. Studies into TXA and hip fracture 72 
surgery have so far provided variable assessments of efficacy in reducing blood loss and 73 
thromboembolic risk with no clear consensus [16-19]. This topic has yet to be investigated in 74 
the form of a systematic review. The purpose of this study was to address this limitation 75 
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within the evidence and systematically examine the available literature regarding the 76 
potential risks and benefits of TXA use in hip fracture surgery with quantification of effect 77 
through meta-analysis of relevant data. 78 
 79 
METHODS 80 
A systematic review and meta-analysis of the use of TXA in hip fracture surgery was 81 
performed and reported according to the Preferred Reporting Items for Systematic Reviews 82 
and Meta-analyses (PRISMA) statement [20]. The review protocol was registered on the 83 
international prospective register of systematic reviews (PROSPERO) prior to 84 
commencement (Registration number CRD42016036806).  85 
Search Strategy 86 
Identification of relevant articles was undertaken through a search of Medline, EMBASE, 87 
AMED, CiNAHL, and the Cochrane Central Registry of Controlled Trials. A search of 88 
unpublished/grey literature databases was undertaken including: OpenGrey, Current Clinical 89 
Trials, the WHO registry of clinical trials and clinaltrials.gov. All electronic searches were 90 
undertaken from database inception to 18th June 2016. A full electronic search strategy for 91 
MEDLINE is shown in Supplementary Table 1. This was adapted for each individual 92 
database. 93 
All reference lists from potentially eligible studies were reviewed. An additional online search 94 
was undertaken using the Google search engine to identify any papers which may have 95 
been omitted from the initial search and to cross-reference against the database search.  96 
Eligibility Criteria  97 
Studies were included if they: presented results evaluating the clinical outcomes and/or 98 
complications regarding the use of TXA in hip fracture surgery. We considered any form of 99 
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hip fracture surgery including: open reduction internal fixation (cannulated screws, dynamic 100 
hip screws, intramedullary devices), hemiarthroplasty and total hip arthroplasty (THA) for 101 
trauma. We excluded papers which were review articles and studies that included 102 
assessment of primary THA (elective), hip arthroscopy or any form of non-trauma hip 103 
surgery. We excluded non-English language publications but did not exclude studies based 104 
on study quality, age of publication or location of study origin. 105 
Study Identification 106 
Two assessors (LF, TS) independently screened the titles and abstracts of the search 107 
outputs for potentially relevant articles which met the eligibility criteria. For those papers 108 
which were deemed potentially eligible, their full-texts were evaluated to determine final 109 
eligibility.  110 
Data Extraction 111 
Data were extracted onto a pre-defined data extraction sheet by one reviewer (LF) and 112 
verified by a second (TS). Data included: study design, research aims, participants 113 
characteristics (age, gender, type of hip fracture, medical morbidity, fracture fixation, 114 
operative details), randomisation method (if applicable), intervention (TXA and control) and 115 
outcome data. Trial authors were contacted for any missing relevant data. 116 
Outcome Measures 117 
The primary outcome measure was frequency of post-operative blood transfusion. The 118 
secondary outcome measures were: post-operative haemoglobin, peri-operative blood loss, 119 
frequency of thromboembolic events, length of hospital stay and complications within the 120 
initial 90-days post-operatively. Outcomes were assessed as either intra-operative, short-121 
term (hospital admission) or longer-term (post-hospital discharge). 122 
Quality Assessment 123 
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Risk of bias assessment was performed by two reviewer independently (LF, TS) using the 124 
Cochrane Collaboration’s risk of bias tool for RCT’s [21] and the Risk of Bias in non-125 
randomised studies – of interventions (ROBINS-I) tool [22]  for observational studies. The 126 
ROBINS-I tool assesses bias across six domains including: confounding, participant 127 
selection, intervention classification, departure from intended interventions, missing data, 128 
measurement of outcomes and selection of reported results. For each domain an outcome of 129 
low, moderate, serious, critical and no information for risk of bias is recorded.  An overall risk 130 
of bias judgement is then determined through combination of the six domains. The Cochrane 131 
Collaboration’s risk of bias tool for RCT’s comprises seven domains including: random 132 
sequence generation, allocation concealment, blinding of participants/personnel, blinding of 133 
outcome assessment, incomplete outcome data, selective reporting and other bias. For each 134 
domain an outcome of low risk, unclear risk or high risk is recorded. There is no overall 135 
assessment of risk of bias. 136 
During the study period any disagreements in quality assessment, study eligibility or data 137 
extraction were resolved through discussion between two reviewers (LF, TS).  138 
Data Analysis 139 
An assessment of clinical heterogeneity was made by analysing the completed data 140 
extraction form. When there was evidence of between-study heterogeneity in population 141 
characteristics, surgical intervention or trial intervention (i.e. TXA), a meta-analysis was 142 
deemed inappropriate and a narrative analysis of the evidence was undertaken. When there 143 
was clinical homogeneity in respect to population characteristics, surgical intervention and 144 
trial intervention, a meta-analysis was deemed appropriate and undertaken for those specific 145 
outcomes. All reported values are for Intravenous TXA unless otherwise stated. 146 
When meta-analysis was undertaken, statistical heterogeneity was assessed using the 147 
inconsistency-value (I2) and Chi-squared tests. When I2 was ≤20% and Chi-squared equated 148 
to p≥0.10, a fixed-effects model meta-analysis was undertaken. When these were not 149 
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satisfied, a random-effects meta-analysis was undertaken [23]. For dichotomous outcomes 150 
including frequency of post-operative blood transfusion, thromboembolic events and 90-day 151 
complications, the relative risk (RR) or risk difference (RD) was estimated with 95% 152 
confidence intervals (CI). A risk difference was calculated if a zero number of events was 153 
reported for an outcome within an individual trial. The number needed to treat (NNT) was 154 
calculated for the primary outcome of post-operative blood transfusion using the inverse of 155 
the absolute risk reduction value. For all continuous outcomes including post-operative 156 
haemoglobin level, peri-operative blood loss and length of hospital stay, the mean difference 157 
(MD) was calculated with 95% CIs. In all analyses, p<0.05 denoted statistically significance.  158 
All analyses were undertaken by two reviewers (LF,TS) using Revman Version 5.3 [24]. All 159 
meta-analysis results are presented in the text as: outcome (RR/RD/MD); 95% CI; 160 
Inconsistency (I2) value; Inconsistency (Chi2) p value; Sample size (N). 161 
A sensitivity analysis was conducted to analyse outcomes in trials without significant 162 
methodological limitation i.e. ambiguity on hip fracture type or surgical intervention. A priori 163 
subgroup analyses included comparison of the TXA intervention to control group on clinical 164 
outcomes stratified by mean age (less than 75 years versus 76 years and over), BMI group 165 
(less than or equal to BMI 40 versus BMI greater than 40), and hip fracture type 166 
(intracapsular vs extracapsular). Assessment was performed by excluding data from studies 167 
which did not meet the subgroup analysis requirements. 168 
The analysis for each outcome was evaluated using the Grades of Recommendation, 169 
Assessment, Development and Evaluation (GRADE) approach by two reviewers (LF, TS) 170 
[25]. This was used to categorise the quality of evidence into four possible levels: high, 171 
moderate, low or very low quality. This approach evaluates the quality of evidence for each 172 
individual analysis (i.e. the body of the literature forming that particular analysis as opposed 173 
to the whole evidence irrespective of whether it was used in an analysis or not).  174 
 175 
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RESULTS 176 
Search Results 177 
A summary of the search results are presented in Figure 1. A total of 102 studies were 178 
identified. Sixteen of these underwent full-text assessment. Subsequently seven met the 179 
eligibility criteria. Two abstract only publications [26, 27] were not included due to incomplete 180 
data and lack of contact details in conference proceedings. A search of the grey/unpublished 181 
literature identified four ongoing trials at various stages of completion [28-31]. 182 
Characteristics of Included Studies 183 
A summary of included study characteristics are shown in Table 1. A total of 770 patients 184 
were included in the analysis. The mean age was 72 years; 65% were female. Of these 341 185 
patients received TXA (321 intravenous (IV) TXA; 20 topical TXA). There was a wide 186 
variation in the frequency and dose of TXA given peri-operatively. Of the seven studies, 187 
three did not differentiate fracture type or management; two studies examined patients 188 
undergoing intracapsular hip fracture treatment (hemi-arthroplasty) alone [17, 19] and two 189 
studies focused on extracapsular hip fractures (one utilised sliding hip screw fixation [18], the 190 
other a short intramedullary nail device [32]).  191 
Quality Assessment 192 
The seven articles identified as suitable for systematic review consisted of six double-blind 193 
RCTs [16-18, 32-34] and one retrospective cohort study [19].  Randomisation methods 194 
included utilisation of opaque sealed envelopes [32, 33], random number techniques [34]  195 
and a computer generated random number table [18]. One study [16] used a stratified 196 
sampling technique via a computer generated randomisation list to ensure equal distribution 197 
of patients undergoing osteosynthesis or hip arthroplasty. One study did not report their 198 
method of randomisation [17].  199 
10 
 
Risk of bias assessment was performed for individual studies with the results shown in 200 
Supplementary table 2. Determination of the risk of bias across studies was also performed 201 
for each outcome measured. 202 
 203 
Synthesis of results 204 
Primary outcome: Post-operative blood transfusion requirement 205 
All seven studies reported the requirement for post-operative blood transfusion [16-19, 32-206 
34]. Meta-analysis showed there was a 46% lower risk of blood transfusion requirement in 207 
those who received intra-venous TXA compared to a placebo/control group (RR: 0.54; 95% 208 
CI: 0.35 to 0.85; I2: 78%; Inconsistency (Chi2) p=<0.0001; N=750; Figure 2). The NNT for 209 
this primary outcome was 8. The funnel plot for the primary outcome is shown in Figure 3. 210 
Secondary outcome: Post-operative haemoglobin level 211 
Six studies reported the requirement for post-operative haemoglobin level [17-19, 32-34]. On 212 
meta-analysis, post-operative haemoglobin was greater in those who received intra-venous 213 
TXA compared to a placebo/control group (MD: 0.81; 95% CI: 0.45 to 1.18; I2: 46%; 214 
Inconsistency (Chi2) p=0.10; N=638; Figure 4).  215 
Secondary outcome: Total post-operative blood loss within the initial post-operative day 216 
Five studies reported the requirement for post-operative blood loss [16, 17, 32-34]. Data 217 
were available to pool outcomes from three studies [17, 33, 34]. On this meta-analysis, post-218 
operative total blood loss was less in those who received intra-venous TXA compared to the 219 
placebo/control group (MD: -341; 95% CI: -672 to -9.87; I2: 100%; Inconsistency (Chi2) 220 
p<0.00001; N=197; Supplementary Figure 1). 221 
There was insufficient data in Zuffery et al [16] to be included in the meta-analysis as post-222 
operative blood loss was only reported at Day 8. They reported no statistically significant 223 
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difference between TXA and placebo groups (444mls; 95% CI: 116 to 804 vs. 307mls; 95% 224 
CI: 90 to 526; respectively; p=0.07). Tengberg et al [32] also only provided data for post-225 
operative blood loss at Day 4, where there was a statistically significant higher blood loss for 226 
control versus TXA (MD: 571; 95% CI: 61.7 to 1080; p=0.029) 227 
Secondary outcome: Peri-operative blood loss 228 
Three studies reported peri-operative blood loss [16, 32, 34]. Meta-analysis showed a 229 
significantly lower blood loss for TXA versus control (MD: -190; 95% CI: -495 to 115; I2: 91%; 230 
Inconsistency (Chi2) p<0.00001; N=249; Supplementary Figure 2). 231 
Secondary outcome: Total Length of Hospital Stay 232 
Two studies reported hospital length of stay [19, 34]. There was no significant difference 233 
between the TXA and placebo/control groups for this outcome (MD: 0.26; 95% CI: -4.05 to 234 
4.56; I2: 77%; Inconsistency (Chi2) p=0.04; N=338; Supplementary Figure 3). 235 
Post-operative complications 236 
Meta-analysis was only possible for six post-operative complications: 30-day mortality; 90 237 
day mortality; stroke; overall thromboembolic events; pulmonary embolism and deep vein 238 
thrombosis. The results of these analyses are shown in table 2. The forest plot for 239 
thromboembolic events is presented in Figure 5. All other forest plots for post-operative 240 
outcomes are displayed in the supplementary material (Supplementary Figures 4 to 8). 241 
There were no statistically significant differences comparing TXA to placebo across the six 242 
analyses.  243 
Zufferey et al [16] reported on a number of other post-operative complications. There were 244 
no significant differences observed for TXA compared to placebo for major bleeding 245 
(inclusion criteria not defined), bacterial infection, pneumonia, lower respiratory tract 246 
infection, urinary tract infection, superficial wound infection, deep wound infection and acute 247 
coronary syndrome.  248 
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GRADE Assessment 249 
The quality of evidence for each eligible outcome was assessed using the GRADE 250 
approach. The results of this are presented in Table 2. These indicated that whilst the quality 251 
of evidence was high the outcome of post-operative haemoglobin level, it was moderate for 252 
those of requirement of post-operative blood transfusion and 30-day mortality. All other 253 
outcomes were either of low or very low quality.   254 
Subgroup analysis 255 
Subgroup analysis was performed as planned where data permitted.  There were five 256 
observed alterations to meta-analysis outcomes. This included a lack of statistical 257 
significance in transfusion rate for TXA versus placebo in those age ≥76 (RR 0.67 (0.37, 258 
1.22); I2: 84%; Inconsistency (Chi2) p=0.002; N=453), in those BMI ≤40 (RR 0.73 (0.49, 259 
1.11); I2: 68%; Inconsistency (Chi2) p=0.02; N=289), and where extracapsular hip fractures 260 
were examined alone (RR 0.67 (0.24, 1.87); I2: 88%; Inconsistency (Chi2) p=0.004; N=172). 261 
When considering peri-operative blood loss there was a lack of significance for TXA versus 262 
placebo in those age ≥76 (MD -47.6 (-127, 31.5); I2: 0%; Inconsistency (Chi2) p=0.97; 263 
N=182). There was also a lack of significance in post-operative haemoglobin for TXA versus 264 
placebo when examining intracapsular hip fractures alone (MD 0.93 (-0.04, 1.91); I2: 79%; 265 
Inconsistency (Chi2) p=0.06; N=309). Results for all other subgroup analyses are presented 266 
in Table 3.  267 
A sensitivity analysis was undertaken removing the results of Lee et al [19] to examine the 268 
influence of any bias inherent in the design of this study. Due to ambiguity regarding the 269 
number of femoral shaft fractures included in their study a similar assessment was also 270 
performed with Vijay et al [33] removed. There were no significant differences in meta-271 
analysis outcomes for either cohort. Results are again presented in Table 3. 272 
 273 
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DISCUSSION 274 
Our systematic review and meta-analysis found moderate-quality evidence that the use of 275 
TXA in hip fracture surgery reduces the absolute risk of requiring a post-operative blood 276 
transfusion by 12%. The NNT for this primary outcome was low at 8.  277 
There is associated high-quality evidence for a higher post-operative haemoglobin level with 278 
TXA and moderate quality evidence for no difference in 30 day mortality. The use of TXA 279 
was not associated with an increase in post-operative stroke, pulmonary embolus, DVT or 280 
composite thromboembolic events. However, the quality of evidence was judged as low for 281 
these outcomes. There is also low quality evidence to suggest a decreased level of post-282 
operative and peri-operative blood loss with TXA and very low quality evidence suggesting 283 
no difference in length of hospital stay. These findings are in keeping with evidence from 284 
other systematic reviews examining the use of TXA in hip and knee arthroplasty [12], as well 285 
as other surgical procedures [13]. 286 
There is a potential financial benefit associated with the use of TXA in hip fracture surgery 287 
when considering blood transfusion. Our estimates suggest that when considering two peri-288 
operative doses of 1g IV TXA, with a cost of £1.50 per 5ml (100mg/ml) for TXA , £635 per 289 
transfusion , and an NNT of 8, this would equate to a saving of approximately £74.13 per 290 
patient who undergo hip fracture surgery on transfusion costs alone. Further cost-benefit 291 
analyses are warranted to estimate the potential value (or not) of TXA on the entire patient 292 
pathway following hip fracture to test whether these suggested benefits are repeatedly 293 
evident following hip fracture surgery. 294 
Subgroup analysis was performed to identify any potential patient or external factors which 295 
may have influenced study findings. A number of differences in the significance of outcome 296 
results were identified. Firstly, a lack of significance was noted for TXA versus placebo 297 
regarding the transfusion rate in those studies with mean age ≥76. This finding could be 298 
explained by previously acknowledged heightened levels of pre-operative anaemia with 299 
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increasing age [35] amplifying the likelihood of transfusion in both groups. Secondly, there 300 
was a lack of significance in transfusion rate for those BMI ≤40. One potential explanation for 301 
this result could relate to greater blood loss in both groups influencing the difference in 302 
transfusion rate. Such higher levels of blood loss of those with a lower BMI would be in 303 
keeping with findings in other orthopaedic surgical procedures [36]. There was also a lack of 304 
significance in transfusion rate with TXA identified for extracapsular hip fractures. Again this 305 
could be explained by recognised greater blood loss and higher levels of pre-operative 306 
anaemia compared to intracapsular fractures [5]. Finally there was a lack of significance for 307 
peri-operative blood loss in those age ≥76 which was felt to relate to the very wide 308 
confidence intervals of the studies used in this analysis. 309 
 Sensitivity analysis with data from Vijay et al [33] and Lee et al [19] excluded did not have a 310 
significant effect on any of the results and therefore neither were felt to have a negative 311 
impact on the overall study outcome. 312 
A number of limitations identified with this study related to the current evidence-base. Firstly, 313 
it was not possible to analyse the potential impact of variation in the dose and timing of TXA 314 
across studies. This was poorly reported and may relate to a current paucity of data 315 
regarding the optimum therapeutic regimen for TXA. The small number of trials presented 316 
meant that sub-group analysis to establish differences between TXA protocols was not 317 
possible. Secondly, major inter-study variation in the transfusion protocol used may explain 318 
some of the differences in outcomes across studies. It is notable that both of the studies with 319 
identified low transfusion thresholds (Hb<9-10 g/dl) [16, 32] did not find a statistically 320 
significant difference in post-operative transfusion rate between TXA and placebo. This is 321 
compounded by the fact that in the Tengberg et al [32] study the TXA group had significantly 322 
lower haemoglobin at admission than the placebo group (11.92 [SD 1.61] vs 12.89g/dl [SD 323 
1.45] respectively; p=0.024). Finally, the GRADE analysis identified a number of the 324 
secondary outcomes as having low or very low quality evidence. This was mainly due to high 325 
heterogeneity across studies, low event numbers and wide confidence intervals. This 326 
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unfortunately limits the conclusions that can be drawn from the evidence and the identified 327 
results for these outcomes must be interpreted with caution.  328 
Four key aspects for future research have been highlighted by this study. Firstly, 329 
understanding the thrombotic risk associated with TXA use in hip fracture surgery is of 330 
paramount importance to determining its clinical utility. Future studies must ensure that 331 
safety outcomes are assessed. Only large studies are likely to provide sufficient cohort size 332 
to accurately determine thrombosis risk. Verification of the optimum timing and dosage of 333 
Intravenous TXA to reduce study heterogeneity would likely be of benefit in this regard. 334 
Secondly, the use of topical TXA in hip fractures is another potential research area of 335 
interest. Only one study [17] examined topical TXA as a treatment option. Their results 336 
indicated an efficacy similar to that of Intravenous TXA when compared to placebo, but with 337 
an improved safety profile. A lack of systemic absorption with topical TXA is one suggested 338 
reason for such an effect. Comparable results have previously been identified with topical 339 
TXA in hip and knee arthroplasty [37-39]. Caution should however be taken when 340 
considering use in hemiarthroplasty as recent research has identified a potential cytotoxic 341 
effect on chondrocytes in an animal model [40]. There is however no suggestion for an 342 
adverse effect with artificial joint materials [41].  343 
Thirdly, evaluation of treatment effect differences between different hip fractures and 344 
treatment options may also be of benefit. Extracapsular hip fracture management has 345 
previously been shown to have a higher amount of blood loss than intracapsular hip 346 
fractures [5, 6]. The complexity and length of THA for hip fracture compared to 347 
hemiarthroplasty has also been shown to lead to a higher degree of blood loss [42]. The 348 
beneficial effects of TXA may be more pronounced in such high-risk groups. 349 
Finally the impact of TXA administration at hospital admission should also be examined. This 350 
approach is already heavily utilised in trauma patients based on results of the landmark 351 
CRASH-2 trial [43]. Hip fractures have been associated with a high initial blood loss that may 352 
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not be apparent on initial haemoglobin testing [5, 44]. Early TXA may provide one method of 353 
reducing pre-operative anaemia, which has previously been identified as risk-factor for 354 
mortality [45]. 355 
 356 
CONCLUSIONS 357 
The clinical importance and financial impact of post-operative blood transfusion requirement 358 
and post-operative anaemia in hip fracture surgery is already well established. Our 359 
systematic review and meta-analysis confirms that TXA is effective at reducing both of these 360 
adverse outcomes in this setting. The presence of an associated thromboembolic risk with 361 
TXA use remains unclear. 362 
 363 
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FIGURE LEGENDS 495 
Figure 1. Flow diagram depicting the study selection process 496 
 497 
Figure 2. Forest-plot of TXA versus control for requirement for blood transfusion 498 
 499 
Figure 3. Funnel plot of TXA versus control for requirement for blood transfusion. 500 
 501 
Figure 4. Forest-plot of TXA versus control for post-operative haemoglobin 502 
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Figure 5. Forest-plot of TXA versus control for thromboembolic events 504 
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SUPPLEMENTARY FIGURE LEGENDS 506 
Supplementary Figure 1. Forest-plot of TXA versus control for total blood loss 507 
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Supplementary Figure 2. Forest-plot of TXA versus control for Peri-operative blood loss 509 
 510 
Supplementary Figure 3. Forest-plot of TXA versus control for length of stay 511 
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 512 
Supplementary Figure 4. Forest-plot of TXA versus control for 90 day mortality 513 
 514 
Supplementary Figure 5. Forest-plot of TXA versus control for Stroke 515 
 516 
Supplementary Figure 6. Forest-plot of TXA versus control for Pulmonary Embolus 517 
 518 
Supplementary Figure 7. Forest-plot of TXA versus control for DVT 519 
Supplementary Figure 8. Forest-plot of TXA versus control for 30 day mortality 520 
 521 
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Table 1. Characteristics of included studies 522 
Paper Study N Gender (M/F) Mean age 
(years) 
ASA grade (3 
or 4) 
Fracture type Fracture surgical 
management 
Duration of 
surgery 
(minutes) 
Intervention  Control 
Lee et al 
2015 [19] 
RCS 271  Interv: 32/52 
Control: 53/134 
Interv: 86.0 
Control: 84.7 
Interv: 57 
Control: 137 
Hip Fracture Hemiarthroplasty: 
271 
Not 
document
ed 
(N: 84) 1g IV TXA given 
at induction. 
(N:187) No 
treatment control. 
Sadeghi 
& Mehr -
Aein 
2007 [34] 
DBL 
blind 
RCT 
67  Interv: 17/15 
Control: 24/11 
Interv: 51.8 
Control: 44.4 
Not 
documented 
Hip Fracture Not documented Not 
document
ed 
(N:32) Single bolus of 
15mg/kg IV TXA given at 
induction. 
(N:35) Same volume 
of IV normal saline 
given to controls. 
Zuffery at 
al. 2010 
[16] 
DBL 
blind 
RCT 
110  Interv: 10/47 
Control: 4/49 
Interv: 81 
Control: 82 
Interv: 19 
Control: 20 
Cervical: 45 
Trochanteric: 19 
Unstable 
trochanteric/inter/su
btrochanternic: 46 
THR: 45 
Hemiarthroplasty: 2 
SHS: 41 
IMN: 22 
Interv: 
64.0 
Control: 
64.0 
(N:57) Two doses of IV 
TXA – 15mg/kg given at 
induction then another 3 
hours later. 
(N:53) Control group 
received 2 doses of 
IV placebo at same 
intervals. 
Emara 
2014 [17] 
DBL 
blind 
RCT 
60  
 
Interv (IV): 12/8 
Interv (Topical): 
10/10 
Control: 14/6 
Interv (IV): 
56.5 
Interv 
(Topical): 55 
Control: 56 
Not 
documented 
Hip Fracture Hemiarthroplasty: 
60 
 
Interv (IV): 
2.3 hrs 
Interv 
(Topical): 
2.3 hrs 
(N:20) IV TXA 10mg/kg 
as bolus pre incision then 
5mg/kg/h infusion until 
end  
(N:20) Topical TXA 
100mls NS with 1.5g TXA 
poured into surgical field 
for 5 mins 
(N:20) Control 
received 20ml of 
normal saline pre-
incision and 80ml/h 
of normal saline until 
end.100ml of normal 
saline poured into 
surgical field for 5 
mins 
Mohib et 
al. 2015 
[18] 
DBL 
blind 
RCT 
100  
 
Interv: 21/29 
Control: 24/26 
Interv: 69.0 
Control: 70.0 
Not 
documented 
Intertrochanteric: 
100 
SHS: 100 Interv: 
112.9 
Control: 
112.3 
(N: 50)Two doses of IV 
10mg/kg TXA at 
induction and 3 hours 
later. 
(N:50) Controls: 
same amount 
saline. 
Vijay et al 
2013 [33] 
DBL 
blind 
RCT 
90 Interv: 10/35 
Control: 10/35 
Interv: 49.3 
Control: 48.8 
Interv: 0 
Control: 0 
Hip and Femoral 
fracture. No further 
details provided. 
ORIF; 
hemiarthroplasty; 
THR. Frequencies 
not documented. 
Interv: 
118.7 
Control: 
117.3 
(N: 45) 10mg/kg body 
weight IV TXA given 
15min prior to incision. 
(N:45) Controls: 
1mg/kg body weight 
IV saline. 
Tengberg 
et al 2016 
[32]  
DBL 
blind 
RCT 
72 Interv: 7/26 
Control: 14/25 
Interv: 79.8 
Control: 75 
Interv: 5 
Control: 12 
Extracapsular (AO 
type 31-A2.2 to 31-
A3): 72 
Short intramedullary 
nail: 72 
Not 
document
ed 
(N: 33) 1g IV TXA as 
bolus pre incision then 
post-op 24hr infusion of 
3g TXA  
(N: 39) Controls: 
5ml saline given pre 
incision and then 24 
hour infusion of 
1litre IV saline 
Abbreviations: DBL = Double; RCT = Randomised controlled trial; RCS = Retrospective cohort study; Interv = Intervention group; THR = Total Hip replacement; SHS = Sliding 523 
hip screw; IMN = Intramedullary nail; ORIF = Open reduction internal fixation  524 
 525 
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Table 2. Synthesis of results for all outcomes & GRADE assessment: summary of findings 
 
Outcomes Intervention 
  
Control 
 
Relative 
effect 
(95% CI) 
Inconsistency 
value (I2) 
Inconsistency 
(Chi2) p value 
Number of 
participants 
[Studies] 
Quality 
of 
evidence 
Comments 
Post-operative 
blood transfusion  
85 of 321 166 of 
429 
RR 0.54 
(0.35, 0.85) 
78% p<0.0001 750 [16-19, 
32-34] 
Moderate Serious imprecision 
Post-operative 
haemoglobin 
10.5 g/dl 10.0 g/dl MD 0.81 
(0.45, 1.18) 
46% p=0.10 638 [17-19, 
32-34] 
High  
Blood loss on 1st 
post-operative day 
467mls 780mls MD -341 (-
672, -9.87) 
100% p<0.0001 197 [17, 31, 
34] 
Low Serious 
inconsistency & 
serious imprecision 
Peri-operative 
blood loss 
415mls 568mls MD -190 (-
495, 115) 
91% p<0.0001 249 [16, 32, 
34] 
Low Serious 
inconsistency & 
serious imprecision 
Length of hospital 
stay 
16.4 days 16.1 
days 
MD 0.26 (-
4.05, 4.56) 
77% p=0.04 338 [19, 34] Very low Serious risk of bias, 
serious 
inconsistency & 
serious imprecision 
Post-operative 
complications: 30 
day mortality 
9 of 206 11 of 
314 
RR 1.33 
(0.53, 3.34) 
0% p=0.48 520 [16,19, 32, 
34] 
Moderate Serious risk of bias 
Post-operative 
complications: 
Stroke 
2 of 110 1 of 112 RR 1.49 
(0.24, 9.25) 
0% p=0.60 222 [16, 17, 
32] 
Low Very serious  
imprecision 
Post-operative 
complications: 
Thromboembolic 
events 
16 of 289 10 of 
394 
RD 0.01 (-
0.03, 0.05) 
* 
68% p=0.007 683 [16-19, 
32, 31] 
Low serious 
inconsistency & 
serious imprecision 
Post-operative 
complications: 
Pulmonary embolus 
0 of 205 0 of 207 RD 0.00 (-
0.02, 0.02) 
* 
0% p=1.00 412 [16-18, 
32, 33] 
Low Very serious 
imprecision 
Post-operative 
complications: DVT 
10 of 172 4 of 168 RD 0.01 (-
0.03, 0.04) 
* 
43% p=0.13 412 [16-18, 
32, 33] 
Low Serious 
inconsistency & 
serious imprecision 
Abbreviations: GRADE = Grading of Recommendations Assessment, Development and Evaluation; 526 
CI =Confidence interval; RR =Relative risk; RD = Risk difference; MD = Mean difference. * risk difference calculated given zero-events were reported in some 527 
studies. 528 
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Table 3. Subgroup & Sensitivity analysis 529 
 530 
Subgroup 
Analysis 
Variable 
[Studies] 
Transfusion Post-operative 
haemoglobin 
Day 1 
post-
operative 
blood loss 
Peri-operative 
blood loss 
Total 
Length of 
Hospital 
Stay 
Thromboembolic 
events 
30 day 
mortality 
90 day 
mortality 
PE DVT Stroke 
             
Age ≥76 
[16,19,32] 
RR 0.67 
(0.37, 1.22); 
I2: 84%; 
Inconsistency 
Chi2 p=0.002; 
N=453 * 
 
 
MD 0.50 (0.10, 
0.89); I2: 0%; 
Inconsistency 
Chi2 p=0.87; 
N=341 
 MD -47.6 (-
127, 31.5); I2: 
0%; 
Inconsistency 
Chi2 p=0.97; 
N=182 * 
 RD 0.00 (-0.07, 
0.08); I2: 69%; 
Inconsistency 
Chi2 p=0.04; 
N=453 
RR 1.61 (0.64, 
4.03); I2: 0%; 
Inconsistency 
Chi2 p=0.41; 
N=453 
 RD 0.00 (-
0.03, 0.03); I2: 
0%; 
Inconsistency 
Chi2 p=1.00; 
N=182 
RD 0.01 (-
0.06, 0.07); I2: 
9%; 
Inconsistency 
Chi2 p=0.29; 
N=182 
RD 0.04 (-
0.04, 0.04); I2: 
0%; 
Inconsistency 
Chi2 p=0.32; 
N=182 
 ≤75 
[17,18,33,34] 
RR 0.48 
(0.33, 0.72); 
I2: 10%;  
Inconsistency 
Chi2 p=0.35; 
N=297 
 
MD 1.03 (0.46, 
1.60); I2: 64%; 
Inconsistency 
Chi2 p=0.0004; 
N=297 
   RD 0.03 (-0.06, 
0.12); I2: 84%; 
Inconsistency 
Chi2 p=0.002; 
N=230 
     
             
BMI ≤40 
[16,17,32,34] 
RR 0.73 
(0.49, 1.11); 
I2: 68%; 
Inconsistency 
Chi2 p=0.02; 
N=289 * 
MD 1.34 (0.76, 
1.93); I2: 0%; 
Inconsistency 
Chi2 p=0.79; 
N=179 
MD: -461 (-
478, -444); 
I2: 0%; 
Inconsisten
cy Chi2 
p=0.43; 
N=107 
  RD 0.08 (-0.10, 
0.26); I2: 82%; 
Inconsistency  
Chi2 p=0.003; 
N=222 
RR 2.26 (0.48, 
10.63); I2: 0%; 
Inconsistency  
Chi2 p=0.42; 
N=247 
 RD 0.00 (-
0.03, 0.03); I2: 
0%; 
Inconsistency  
Chi2 p=1.00; 
N=222 
RD 0.04 (-
0.02, 0.11); I2: 
65%; 
Inconsistency  
Chi2 p=0.20; 
N=222 
 
 >40            
             
Hip 
fracture 
type 
Intracapsular 
[17,19] 
           
 Extracapsular 
[18,32] 
RR 0.67 
(0.24, 1.87); 
I2: 88%; 
Inconsistency  
Chi2 p=0.004; 
N=172 * 
MD 1.40 (-
0.79, 2.01); I2: 
0%; 
Inconsistency  
Chi2 p=0.85; 
N=212 
   RD -0.02 (-0.07, 
0.04); I2: 40%; 
Inconsistency  
Chi2 p=0.20; 
N=172 
  RD 0.00 (-
0.03, 0.03); I2: 
0%; 
Inconsistency  
Chi2 p=1.00; 
N=172 
RD -0.01 (-
0.05, 0.03); I2: 
0%; 
Inconsistency  
Chi2 p=0.49; 
N=172 
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Subgroup 
Analysis 
Variable 
[Studies] 
Transfusion Post-operative 
haemoglobin 
Total post-
operative 
blood loss 
Peri-operative 
blood loss 
Total 
Length of 
Hospital 
Stay 
Thromboembolic 
events 
30 day 
mortality 
90 day 
mortality 
PE DVT Stroke 
             
Vijay et al. 
2013 
removed 
[16-19,32,34] RR 0.58 
(0.36, 0.92); 
I2: 78%; 
Inconsistency  
Chi2 
p=0.0003; 
N=660 
 
MD 1.01 (0.50, 
1.51); I2: 43%; 
Inconsistency  
Chi2 p=0.14; 
N=548 
MD: -461 (-
478, -444); 
I2: 0%; 
Inconsisten
cy Chi2 
p=0.43; 
N=107 
  RD 0.02 (-0.04, 
0.08); I2: 75%; 
Inconsistency  
Chi2 p=0.0003; 
N=593 
  RD 0.02 (-
0.02, 0.02); I2: 
0%; 
Inconsistency 
Chi2 p=1.00; 
N=322 
RD 0.03 (-
0.02, 0.08); I2: 
58%; 
Inconsistency 
Chi2 p=0.07; 
N=322 
 
             
Lee et al. 
2015 
removed 
[16-18,32-34] RR 0.60 
(0.39, 0.92); 
I2: 76%; 
Inconsistency  
Chi2 p=0.001; 
N=479  
 
MD 1.00 (0.47, 
1.54); I2: 53%; 
Inconsistency  
Chi2 p=0.08; 
N=369 
   RD 0.02 (-0.04, 
0.09); I2: 77%; 
Inconsistency  
Chi2 p=0.001; 
N=412 
RR 2.26 (0.48, 
10.63); I2: 0%; 
Inconsistency  
Chi2 p=0.42; 
N=479 
    
Abbreviations: CI = confidence intervals; I2 = inconsistency value; N = number of cases; RR = Risk ratio; RD = risk difference (calculated given zero-events were reported in some studies). * denotes 531 
result that has ceased to become statistically significant after subgroup analysis. 532 
 533 
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Supplementary Table 1. Search strategy 534 
 535 
 536 
 537 
 538 
 539 
 540 
 541 
 542 
 543 
 544 
1. Tranexamic acid  
2. hip fracture  
3. femoral fracture  
4. neck of femur  
5. extracapsular  
6. intracapsular  
7. subcapital 
8. transcervical 
9. basicervical  
10. intertrochanteric  
11. subtrochanteric 
12. hemiarthroplasty 
13. total hip arthroplasty 
14. sliding hip screw  
15. dynamic hip screw 
16. intramedullary nail 
17. femoral nail  
18. cannulated screws 
19. open reduction internal fixation 
20. OR/1-11 
21. OR/12-19 
22. AND/1,20,21 
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Supplementary table 2. Risk of bias assessment for individual studies 545 
 546 
RCT Studies Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
& personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome data 
Selective 
reporting 
Other bias Other bias 
explanation 
Emara et al 
2014 [17] 
Unclear risk Unclear risk Unclear risk Unclear risk Low risk High risk Low risk  
Mohib et al 
2015 [18] 
Low risk Unclear risk Low risk Low risk Low risk Low risk Low risk  
Sadeghi et al 
2007 [34] 
Low risk Low risk Low risk Unclear risk Unclear risk High risk Low risk  
Vijay et al 2013 
[33] 
High risk Unclear risk Unclear risk Unclear risk Low risk Low risk High risk unclear frequency 
of distal or proximal 
femoral fracture 
Zufferey et al 
2010 [16] 
Low risk Low risk Low risk Low risk Low risk Low risk Low risk  
Tengberg et al 
2015 [32] 
Low risk Low risk Low risk Low risk Low risk Low risk High risk Significant baseline 
differences in 
treatment groups 
Observational 
studies 
Bias due to 
confounding 
Bias in 
participant 
selection 
Bias in 
classification 
of 
interventions 
Bias due to 
departures 
from intended 
interventions 
Bias due to 
missing data 
Bias in 
measurement 
of outcomes 
Bias in 
selection of 
the reported 
result 
Overall bias 
Lee et al 2015 
[19] 
Serious risk Low risk Moderate risk Low risk Low risk Moderate risk Moderate risk Serious risk 
Risk of bias assessment was performed using the Cochrane Collaboration’s risk of bias tool for RCT’s. Each domain was classified as either unclear, low or high risk. The Risk 547 
of Bias in non-randomised studies – of interventions (ROBINS-I) tool was used for observational studies. Each domain was classified as low risk, moderate risk, serious risk, 548 
and critical risk or not interpretable. An overall bias assessment was then made using the same scale. 549 
 550 
27 
 
Figure 1. Flow diagram depicting the study selection process 551 
 552 
 553 
 554 
 555 
  556 
28 
 
Figure 2. Forest-plot of TXA versus control for requirement for blood transfusion 557 
 558 
 559 
  560 
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Figure 3. Funnel plot of TXA versus control for requirement for blood transfusion. 561 
 562 
 563 
  564 
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Figure 4. Forest-plot of TXA versus control for post-operative haemoglobin 565 
 566 
 567 
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Figure 5. Forest-plot of TXA versus control for thromboembolic events 569 
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